Journal: Materials Today Bio
Article Title: Feasibility of combining JAK1 gene editing via CRISPR-CasRx with EGCG–lactoferrin nanoparticle therapy in a microneedle-based platform for atopic dermatitis
doi: 10.1016/j.mtbio.2026.102884
Figure Lengend Snippet: Regulation of MN patches on the inflammation, JAK1 and Nrf2/HO-1 pathways in AD mice. ( a-c ) Levels of IL-1β, IL-4, and IL-13 in the dorsal skin. ( d, e ) Levels of TSLP and IgE in the serum. ( f ) Protein expression of JAK1 in the dorsal skin. ( g ) Quantitative analysis of JAK1 protein levels from (f). ( h ) 8-OHdG levels in the dorsal skin. ( i ) Fluorescent immunostaining of Nrf2, with the merged image showing DAPI staining (red: Nrf2, blue: DAPI). ( j ) Quantitative analysis of Nrf2 protein expression from (i). ( k ) Fluorescent immunostaining of HO-1, along with the merged image showing DAPI staining (red: HO-1, blue: DAPI). ( l ) Quantitative analysis of HO-1 protein expression from (k). Data are presented as mean ± SD (n = 6). Bars sharing the same letter are not significantly different, whereas those with different letters are statistically significant (p < 0.05).
Article Snippet: The 8-OHdG ELISA Kit was purchased from Youersheng Technology Co., Ltd (Wuhan, China), and the mouse IL-13 uncoated ELISA kit was purchased from Lianke Biotechnology Co., Ltd (Hangzhou, China).
Techniques: Expressing, Immunostaining, Staining